Bioengineered siRNA-Based Nanoplatforms Targeting Molecular Signaling Pathways for the Treatment of Triple Negative Breast Cancer: Preclinical and Clinical Advancements
Related Experiment Video
Updated: Dec 7, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Dima Hattab1, Athirah Bakhtiar2
1School of Pharmacy, University of Jordan, Queen Rania Street, 11942 Amman, Jordan.
Abstract:
Triple negative breast cancer (TNBC) is one of the most aggressive types of breast cancer. Owing to the absenteeism of hormonal receptors expressed at the cancerous breast cells, hormonal therapies and other medications targeting human epidermal growth factor receptor 2 (HER2) are ineffective in TNBC patients, making traditional chemotherapeutic agents the only current appropriate regimen. Patients' predisposition to relapse and metastasis, chemotherapeutics' cytotoxicity and resistance and poor prognosis of TNBC necessitates researchers to investigate different novel-targeted therapeutics. The role of small interfering RNA (siRNA) in silencing the genes/proteins that are aberrantly overexpressed in carcinoma cells showed great potential as part of TNBC therapeutic regimen. However, targeting specificity, siRNA stability, and delivery efficiency cause challenges in the progression of this application clinically. Nanotechnology was highlighted as a promising approach for encapsulating and transporting siRNA with high efficiency-low toxicity profile. Advances in preclinical and clinical studies utilizing engineered siRNA-loaded nanotherapeutics for treatment of TNBC were discussed. Specific and selective targeting of diverse signaling molecules/pathways at the level of tumor proliferation and cell cycle, tumor invasion and metastasis, angiogenesis and tumor microenvironment, and chemotherapeutics' resistance demonstrated greater activity via integration of siRNA-complexed nanoparticles.
Insights
Triple negative breast cancer (TNBC) treatment faces challenges due to its aggressive nature. Nanoparticle-delivered small interfering RNA (siRNA) offers a promising targeted therapeutic strategy to overcome these limitations.
Area of Science:
- Oncology
- Nanomedicine
- Molecular Biology
Background:
- Triple negative breast cancer (TNBC) lacks targeted therapies, necessitating novel treatment approaches.
- Traditional chemotherapy for TNBC has limitations including cytotoxicity and resistance.
- Small interfering RNA (siRNA) shows potential for gene silencing in TNBC but faces delivery challenges.
Purpose of the Study:
- To review advances in siRNA-loaded nanotherapeutics for TNBC treatment.
- To highlight the potential of nanotechnology in overcoming siRNA delivery obstacles.
- To discuss the targeted therapeutic applications of siRNA-nanoparticles in TNBC.
Main Methods:
- Review of preclinical and clinical studies on siRNA-loaded nanotherapeutics for TNBC.
- Discussion of nanotechnology-based strategies for siRNA encapsulation and delivery.
- Analysis of targeted signaling pathways affected by siRNA-nanoparticles.
Main Results:
- Engineered siRNA-loaded nanotherapeutics demonstrate high efficiency and low toxicity in TNBC models.
- Targeted delivery of siRNA via nanoparticles effectively inhibits tumor proliferation, invasion, metastasis, and angiogenesis.
- siRNA-nanoparticles show potential in overcoming chemoresistance and modulating the tumor microenvironment.
Conclusions:
- Nanotechnology-based siRNA delivery represents a promising strategy for TNBC therapy.
- Targeted silencing of specific genes/pathways using siRNA-nanoparticles can enhance treatment efficacy.
- Further development of siRNA-loaded nanotherapeutics holds significant potential for improving TNBC patient outcomes.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...

